These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 35952703)

  • 1. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
    Mazur NI; Terstappen J; Baral R; Bardají A; Beutels P; Buchholz UJ; Cohen C; Crowe JE; Cutland CL; Eckert L; Feikin D; Fitzpatrick T; Fong Y; Graham BS; Heikkinen T; Higgins D; Hirve S; Klugman KP; Kragten-Tabatabaie L; Lemey P; Libster R; Löwensteyn Y; Mejias A; Munoz FM; Munywoki PK; Mwananyanda L; Nair H; Nunes MC; Ramilo O; Richmond P; Ruckwardt TJ; Sande C; Srikantiah P; Thacker N; Waldstein KA; Weinberger D; Wildenbeest J; Wiseman D; Zar HJ; Zambon M; Bont L
    Lancet Infect Dis; 2023 Jan; 23(1):e2-e21. PubMed ID: 35952703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.
    Frenkel LD; Gaur S; Bellanti JA
    Allergy Asthma Proc; 2023 Jul; 44(4):220-228. PubMed ID: 37236777
    [No Abstract]   [Full Text] [Related]  

  • 3. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
    Scotta MC; Stein RT
    J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S4-S11. PubMed ID: 36402228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
    Zheng Z
    Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.
    Mazur NI; Higgins D; Nunes MC; Melero JA; Langedijk AC; Horsley N; Buchholz UJ; Openshaw PJ; McLellan JS; Englund JA; Mejias A; Karron RA; Simões EA; Knezevic I; Ramilo O; Piedra PA; Chu HY; Falsey AR; Nair H; Kragten-Tabatabaie L; Greenough A; Baraldi E; Papadopoulos NG; Vekemans J; Polack FP; Powell M; Satav A; Walsh EE; Stein RT; Graham BS; Bont LJ;
    Lancet Infect Dis; 2018 Oct; 18(10):e295-e311. PubMed ID: 29914800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.
    Shan J; Britton PN; King CL; Booy R
    Influenza Other Respir Viruses; 2021 Jul; 15(4):539-551. PubMed ID: 33764693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory syncytial virus immunoprophylaxis: Novel opportunities and a call for equity.
    Rzymski P; Gwenzi W
    J Med Virol; 2024 Feb; 96(2):e29453. PubMed ID: 38305000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing RSV in children and adults: A vaccine update.
    Campos-Outcalt D
    J Fam Pract; 2023 Nov; 72(9):E17-E20. PubMed ID: 37976341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus vaccine development.
    Kahn JS
    Curr Opin Pediatr; 2000 Jun; 12(3):257-62. PubMed ID: 10836163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in RSV vaccine research and development - A global agenda.
    Higgins D; Trujillo C; Keech C
    Vaccine; 2016 Jun; 34(26):2870-2875. PubMed ID: 27105562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of mRNA vaccines against respiratory syncytial virus (RSV).
    Qiu X; Xu S; Lu Y; Luo Z; Yan Y; Wang C; Ji J
    Cytokine Growth Factor Rev; 2022 Dec; 68():37-53. PubMed ID: 36280532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RSV Prevention Within Reach for Older Infants and Toddlers: The Role of Active Immunization.
    Mejias A; Ramilo O
    J Pediatric Infect Dis Soc; 2024 Jul; 13(Supplement_2):S125-S130. PubMed ID: 38995087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priorities for developing respiratory syncytial virus vaccines in different target populations.
    Drysdale SB; Barr RS; Rollier CS; Green CA; Pollard AJ; Sande CJ
    Sci Transl Med; 2020 Mar; 12(535):. PubMed ID: 32188721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants.
    Syed YY
    Paediatr Drugs; 2023 Nov; 25(6):729-734. PubMed ID: 37831328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing Pediatric Respiratory Syncytial Virus Infection.
    Domachowske J; Halczyn J; Bonville CA
    Pediatr Ann; 2018 Sep; 47(9):e371-e376. PubMed ID: 30208197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
    Sparrow E; Adetifa I; Chaiyakunapruk N; Cherian T; Fell DB; Graham BS; Innis B; Kaslow DC; Karron RA; Nair H; Neuzil KM; Saha S; Smith PG; Srikantiah P; Were F; Zar HJ; Feikin D
    Vaccine; 2022 Jun; 40(26):3506-3510. PubMed ID: 35184927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider evaluation of vaccine candidates for the prevention of respiratory syncytial virus disease in RSV-naïve infants.
    Browne SK; Beeler JA; Roberts JN
    Vaccine; 2020 Jan; 38(2):101-106. PubMed ID: 31706809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.